Ticker
PFE

Price
47.90
Stock movement up
+0.47 (0.99%)
Company name
Pfizer Inc
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-General
Market cap
268.76B
Ent value
367.45B
Price/Sales
2.91
Price/Book
-
Div yield
3.34%
Div growth
6.53%
Growth years
11
FCF payout
25.33%
Trailing P/E
10.77
Forward P/E
8.77
PEG
2.00
EPS growth
14.70%
1 year return
0.82%
3 year return
13.22%
5 year return
8.75%
10 year return
7.78%
Last updated: 2022-08-25

BUSINESS INSIGHT

Segment Revenues ($M)

Loading...

Geographic Revenues ($M)

Loading...

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share1.60
Dividend yield3.34%
Payout frequencyQuarterly
Maximum yield5.34%
Average yield3.70%
Minimum yield2.61%
Discount to avg yield-10.76%
Upside potential-9.71%
Yield as % of max yield62.60%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield3.34%
Current yield distribution74.84%
Yield at 100% (Min)2.61%
Yield at 90%3.11%
Yield at 80%3.28%
Yield at 50% (Median)3.73%
Yield at 20%4.07%
Yield at 10%4.26%
Yield at 0% (Max)5.34%

Dividend per share

Loading...
Dividend per share data
Years of growth11 years
CCC statusDividend Contender
Dividend per share1.60
Payout frequencyQuarterly
Ex-div date28 Jul 2022
EPS (TTM)-
EPS (1y forward)5.46
EPS growth (5y)14.70%
EPS growth (5y forward)5.37%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
PFES&P500
DGR MR2.56%15.44%
DGR TTM3.92%7.80%
DGR 3 years6.58%3.88%
DGR 5 years6.53%4.73%
DGR 10 years7.48%8.30%
DGR 15 years3.66%5.82%
Time since last change announced296 days
EPS growth (5y)14.70%
EPS growth (5y forward)5.37%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM26.26%25.33%
Average--
Forward29.30%-

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E10.77
Price to OCF9.58
Price to FCF10.38
Price to EBITDA11.65
EV to EBITDA15.93

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales2.91
Price to Book-
EV to Sales3.98

FINANCIALS

Per share

Loading...
Per share data
Current share count5.61B
EPS (TTM)-
FCF per share (TTM)-

Income statement

Loading...
Income statement data
Revenue (TTM)92.37B
Gross profit (TTM)55.77B
Operating income (TTM)25.48B
Net income (TTM)24.97B
EPS (TTM)-
EPS (1y forward)5.46

Margins

Loading...
Margins data
Gross margin (TTM)60.38%
Operating margin (TTM)27.59%
Profit margin (TTM)27.03%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash2.47B
Net receivables16.34B
Total current assets54.42B
Goodwill50.21B
Intangible assets29.82B
Property, plant and equipment0.00
Total assets183.84B
Accounts payable5.51B
Short/Current long term debt35.05B
Total current liabilities39.27B
Total liabilities101.16B
Shareholder's equity0.00
Net tangible assets2.40B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)28.04B
Capital expenditures (TTM)2.16B
Free cash flow (TTM)25.89B
Dividends paid (TTM)6.56B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-
Return on Assets-
Return on Invested Capital-
Cash Return on Invested Capital-

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open47.52
Daily high47.95
Daily low47.27
Daily Volume14.4M
All-time high61.25
1y analyst estimate58.42
Beta0.68
EPS (TTM)-
Dividend per share1.60
Ex-div date28 Jul 2022
Next earnings date31 Oct 2022

Downside potential

Loading...
Downside potential data
PFES&P500
Current price drop from All-time high-21.80%-12.18%
Highest price drop-76.70%-56.47%
Date of highest drop2 Mar 20099 Mar 2009
Avg drop from high-29.99%-11.38%
Avg time to new high35 days12 days
Max time to new high5620 days1805 days
COMPANY DETAILS
PFE (Pfizer Inc) company logo
Marketcap
268.76B
Marketcap category
Large-cap
Description
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Employees
79000
SEC filings
CEO
Albert Bourla
Country
USA
City
New York
Stock type
Common stock
CCC status
Dividend Contender
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
What's better than a growth stock that's performed well in the past? The answer is easy: A growth stock that should perform well in the future. Here's why they chose Eli Lilly (NYSE: LLY), Pfizer (N...
October 1, 2022
Biohaven Pharmaceuticals (BHVN) suffers a setback as verdiperstat fails to meet the primary and secondary endpoints in an ALS study.
September 30, 2022
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of inco...
September 30, 2022
Around 3.2 million people in the United States received updated COVID-19 booster shots over the past week, the Centers for Disease Control and Prevention said on Thursday. The 7.6 million figure repr...
September 29, 2022
The EMA accepts Moderna's (MRNA) regulatory filing seeking authorization for bivalent COVID-19 booster vaccine, mRNA-1273.222, designed to target the Omicron BA.4 and BA.5 subvariants.
September 29, 2022
Pfizer (PFE) and BioNTech seek to expand the EU label of their Omicron BA.4/BA.5-adapting bivalent COVID vaccine for children. It is already authorized for use in adolescents and adults.
September 29, 2022
Biohaven Pharmaceutical Holding Company Ltd said on Thursday its experimental drug to treat amyotrophic lateral sclerosis (ALS) failed a clinical study, the second therapy by the drugmaker to fail tri...
September 29, 2022
Merck & Co Inc (NYSE: MRK) signed a cooperation framework agreement in China for its COVID-19 antiviral pills, which were co-developed by Ridgeback Therapeutics. The pharma giant has granted Sinopharm...
September 29, 2022
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 14x, you may...
September 29, 2022
Data is still scarce on latest COVID-19 boosters
September 28, 2022
Next page